Inotiv, Inc. Logo

Inotiv, Inc.

NOTV

(1.5)
Stock Price

2,68 USD

-24.94% ROA

-43.49% ROE

-0.48x PER

Market Cap.

47.847.360,00 USD

216.29% DER

0% Yield

-19.8% NPM

Inotiv, Inc. Stock Analysis

Inotiv, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Inotiv, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.18x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (11), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

5 ROE

Negative ROE (-113.62%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-76.38%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 DER

The stock is burdened with a heavy load of debt (151%), making it financially unstable and potentially risky for investors.

8 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Inotiv, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Inotiv, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Inotiv, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Inotiv, Inc. Revenue
Year Revenue Growth
1997 14.900.000
1998 18.200.000 18.13%
1999 19.900.000 8.54%
2000 19.223.301 -3.52%
2001 25.274.648 23.94%
2002 26.513.046 4.67%
2003 29.838.954 11.15%
2004 37.152.000 19.68%
2005 42.395.046 12.37%
2006 43.047.675 1.52%
2007 45.245.000 4.86%
2008 41.697.000 -8.51%
2009 31.784.000 -31.19%
2010 28.781.000 -10.43%
2011 33.144.000 13.16%
2012 28.208.000 -17.5%
2013 22.068.000 -27.82%
2014 24.584.000 10.23%
2015 22.698.000 -8.31%
2016 20.441.000 -11.04%
2017 24.242.000 15.68%
2018 26.346.000 7.99%
2019 43.616.000 39.6%
2020 60.469.000 27.87%
2021 89.605.000 32.52%
2022 547.656.000 83.64%
2023 572.425.000 4.33%
2024 423.144.000 -35.28%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Inotiv, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1997 1.600.000
1998 2.200.000 27.27%
1999 2.000.000 -10%
2000 1.805.933 -10.75%
2001 1.611.045 -12.1%
2002 1.521.001 -5.92%
2003 1.326.933 -14.63%
2004 1.100.000 -20.63%
2005 1.326.032 17.05%
2006 1.444.441 8.2%
2007 881.000 -63.95%
2008 781.000 -12.8%
2009 762.000 -2.49%
2010 546.000 -39.56%
2011 534.000 -2.25%
2012 542.000 1.48%
2013 454.000 -19.38%
2014 658.000 31%
2015 715.000 7.97%
2016 496.000 -44.15%
2017 465.000 -6.67%
2018 596.000 21.98%
2019 627.000 4.94%
2020 950.000 34%
2021 405.000 -134.57%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Inotiv, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 5.900.000
1998 6.800.000 13.24%
1999 6.500.000 -4.62%
2000 6.390.507 -1.71%
2001 7.018.657 8.95%
2002 7.416.034 5.36%
2003 8.283.280 10.47%
2004 10.180.000 18.63%
2005 12.779.425 20.34%
2006 14.725.986 13.22%
2007 10.429.000 -41.2%
2008 11.734.000 11.12%
2009 7.674.000 -52.91%
2010 6.119.000 -25.41%
2011 5.564.000 -9.97%
2012 5.524.000 -0.72%
2013 4.405.000 -25.4%
2014 4.940.000 10.83%
2015 5.074.000 2.64%
2016 4.581.000 -10.76%
2017 4.901.000 6.53%
2018 5.965.000 17.84%
2019 9.533.000 37.43%
2020 16.977.000 43.85%
2021 30.375.000 44.11%
2022 82.436.000 63.15%
2023 108.227.000 23.83%
2024 67.128.000 -61.22%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Inotiv, Inc. EBITDA
Year EBITDA Growth
1997 1.600.000
1998 1.500.000 -6.67%
1999 2.100.000 28.57%
2000 526.884 -298.57%
2001 5.224.301 89.91%
2002 3.546.521 -47.31%
2003 3.004.660 -18.03%
2004 3.621.000 17.02%
2005 4.679.238 22.62%
2006 1.518.749 -208.1%
2007 5.937.000 74.42%
2008 5.825.000 -1.92%
2009 -1.481.000 493.32%
2010 326.000 554.29%
2011 3.421.000 90.47%
2012 -2.479.000 238%
2013 837.000 396.18%
2014 2.314.000 63.83%
2015 309.000 -648.87%
2016 -2.063.000 114.98%
2017 1.283.000 260.8%
2018 20.000 -6315%
2019 -144.000 113.89%
2020 -3.048.000 95.28%
2021 7.802.000 139.07%
2022 -37.416.000 120.85%
2023 39.861.000 193.87%
2024 -3.928.000 1114.79%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Inotiv, Inc. Gross Profit
Year Gross Profit Growth
1997 9.100.000
1998 10.600.000 14.15%
1999 10.700.000 0.93%
2000 8.640.547 -23.83%
2001 12.120.102 28.71%
2002 10.563.768 -14.73%
2003 10.410.213 -1.48%
2004 11.534.000 9.74%
2005 15.344.031 24.83%
2006 13.809.957 -11.11%
2007 13.792.000 -0.13%
2008 15.333.000 10.05%
2009 7.604.000 -101.64%
2010 7.333.000 -3.7%
2011 10.506.000 30.2%
2012 6.838.000 -53.64%
2013 7.055.000 3.08%
2014 7.962.000 11.39%
2015 7.489.000 -6.32%
2016 4.425.000 -69.24%
2017 7.697.000 42.51%
2018 8.116.000 5.16%
2019 12.921.000 37.19%
2020 18.237.000 29.15%
2021 30.156.000 39.52%
2022 157.212.000 80.82%
2023 165.443.000 4.98%
2024 27.848.000 -494.09%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Inotiv, Inc. Net Profit
Year Net Profit Growth
1997 700.000
1998 400.000 -75%
1999 600.000 33.33%
2000 -1.382.010 143.42%
2001 1.766.757 178.22%
2002 1.066.445 -65.67%
2003 87.306 -1121.5%
2004 -203.000 143.01%
2005 -100.998 -100.99%
2006 -2.609.942 96.13%
2007 926.000 381.85%
2008 -1.489.000 162.19%
2009 -5.463.000 72.74%
2010 -2.691.000 -103.01%
2011 543.000 595.58%
2012 -6.390.000 108.5%
2013 773.000 926.65%
2014 -1.070.000 172.24%
2015 1.089.000 198.26%
2016 -3.230.000 133.72%
2017 884.000 465.38%
2018 -194.000 555.67%
2019 -790.000 75.44%
2020 -4.685.000 83.14%
2021 10.895.000 143%
2022 -337.262.000 103.23%
2023 -105.140.000 -220.77%
2024 -104.348.000 -0.76%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Inotiv, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 -1 0%
2007 0 0%
2008 0 0%
2009 -1 100%
2010 -1 0%
2011 -1 0%
2012 -1 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1 0%
2022 -14 100%
2023 -4 -225%
2024 -4 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Inotiv, Inc. Free Cashflow
Year Free Cashflow Growth
1997 -3.300.000
1998 -2.700.000 -22.22%
1999 -2.500.000 -8%
2000 -2.558.256 2.28%
2001 2.354.371 208.66%
2002 -2.651.779 188.78%
2003 -2.383.972 -11.23%
2004 -734.000 -224.79%
2005 -2.842.403 74.18%
2006 2.157.069 231.77%
2007 2.050.000 -5.22%
2008 -1.115.000 283.86%
2009 1.753.000 163.61%
2010 1.991.000 11.95%
2011 -86.000 2415.12%
2012 -1.290.000 93.33%
2013 1.511.000 185.37%
2014 1.194.000 -26.55%
2015 564.000 -111.7%
2016 -196.000 387.76%
2017 889.000 122.05%
2018 2.170.000 59.03%
2019 -5.101.000 142.54%
2020 -4.910.000 -3.89%
2021 -1.726.000 -184.47%
2022 -41.517.000 95.84%
2023 380.000 11025.53%
2024 -19.227.000 101.98%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Inotiv, Inc. Operating Cashflow
Year Operating Cashflow Growth
1997 800.000
1998 2.400.000 66.67%
1999 1.600.000 -50%
2000 -539.160 396.76%
2001 4.027.782 113.39%
2002 2.032.499 -98.17%
2003 2.945.194 30.99%
2004 2.834.000 -3.92%
2005 -541.250 623.6%
2006 3.843.929 114.08%
2007 2.928.000 -31.28%
2008 598.000 -389.63%
2009 2.587.000 76.88%
2010 2.441.000 -5.98%
2011 1.088.000 -124.36%
2012 -200.000 644%
2013 1.519.000 113.17%
2014 1.684.000 9.8%
2015 2.031.000 17.09%
2016 1.060.000 -91.6%
2017 1.236.000 14.24%
2018 3.487.000 64.55%
2019 1.777.000 -96.23%
2020 1.290.000 -37.75%
2021 10.746.000 88%
2022 -5.217.000 305.98%
2023 27.883.000 118.71%
2024 -14.806.000 288.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Inotiv, Inc. Capital Expenditure
Year Capital Expenditure Growth
1997 4.100.000
1998 5.100.000 19.61%
1999 4.100.000 -24.39%
2000 2.019.096 -103.06%
2001 1.673.411 -20.66%
2002 4.684.278 64.28%
2003 5.329.166 12.1%
2004 3.568.000 -49.36%
2005 2.301.153 -55.05%
2006 1.686.860 -36.42%
2007 878.000 -92.13%
2008 1.713.000 48.74%
2009 834.000 -105.4%
2010 450.000 -85.33%
2011 1.174.000 61.67%
2012 1.090.000 -7.71%
2013 8.000 -13525%
2014 490.000 98.37%
2015 1.467.000 66.6%
2016 1.256.000 -16.8%
2017 347.000 -261.96%
2018 1.317.000 73.65%
2019 6.878.000 80.85%
2020 6.200.000 -10.94%
2021 12.472.000 50.29%
2022 36.300.000 65.64%
2023 27.503.000 -31.99%
2024 4.421.000 -522.1%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Inotiv, Inc. Equity
Year Equity Growth
1997 6.900.000
1998 16.800.000 58.93%
1999 17.400.000 3.45%
2000 16.061.658 -8.33%
2001 17.830.329 9.92%
2002 18.898.364 5.65%
2003 19.726.464 4.2%
2004 19.420.000 -1.58%
2005 19.597.730 0.91%
2006 17.353.539 -12.93%
2007 18.554.000 6.47%
2008 17.795.000 -4.27%
2009 13.120.000 -35.63%
2010 10.667.000 -23%
2011 15.586.000 31.56%
2012 9.590.000 -62.52%
2013 9.459.000 -1.38%
2014 9.536.000 0.81%
2015 10.718.000 11.03%
2016 7.458.000 -43.71%
2017 8.467.000 11.92%
2018 10.884.000 22.21%
2019 10.710.000 -1.62%
2020 7.596.000 -41%
2021 105.128.000 92.77%
2022 359.766.000 70.78%
2023 268.490.000 -34%
2024 364.214.000 26.28%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Inotiv, Inc. Assets
Year Assets Growth
1997 15.900.000
1998 22.300.000 28.7%
1999 26.300.000 15.21%
2000 26.662.366 1.36%
2001 27.976.654 4.7%
2002 33.462.611 16.39%
2003 44.985.231 25.61%
2004 46.795.000 3.87%
2005 47.838.429 2.18%
2006 42.313.879 -13.06%
2007 42.037.000 -0.66%
2008 40.347.000 -4.19%
2009 32.585.000 -23.82%
2010 29.743.000 -9.56%
2011 32.346.000 8.05%
2012 26.975.000 -19.91%
2013 25.597.000 -5.38%
2014 23.774.000 -7.67%
2015 23.815.000 0.17%
2016 21.139.000 -12.66%
2017 20.417.000 -3.54%
2018 31.268.000 34.7%
2019 41.980.000 25.52%
2020 61.593.000 31.84%
2021 321.856.000 80.86%
2022 962.900.000 66.57%
2023 856.530.000 -12.42%
2024 774.588.000 -10.58%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Inotiv, Inc. Liabilities
Year Liabilities Growth
1997 9.000.000
1998 5.500.000 -63.64%
1999 8.900.000 38.2%
2000 10.600.708 16.04%
2001 10.146.325 -4.48%
2002 14.564.247 30.33%
2003 25.258.767 42.34%
2004 27.375.000 7.73%
2005 28.240.699 3.07%
2006 24.960.340 -13.14%
2007 23.483.000 -6.29%
2008 22.552.000 -4.13%
2009 19.465.000 -15.86%
2010 19.076.000 -2.04%
2011 16.760.000 -13.82%
2012 17.385.000 3.6%
2013 16.138.000 -7.73%
2014 14.238.000 -13.34%
2015 13.097.000 -8.71%
2016 13.681.000 4.27%
2017 11.950.000 -14.49%
2018 20.384.000 41.38%
2019 31.270.000 34.81%
2020 53.997.000 42.09%
2021 216.728.000 75.09%
2022 603.134.000 64.07%
2023 588.040.000 -2.57%
2024 592.481.000 0.75%

Inotiv, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
19.28
Net Income per Share
-3.82
Price to Earning Ratio
-0.48x
Price To Sales Ratio
0.1x
POCF Ratio
3.34
PFCF Ratio
-5.4
Price to Book Ratio
0.26
EV to Sales
0.92
EV Over EBITDA
162.3
EV to Operating CashFlow
32.32
EV to FreeCashFlow
-52.26
Earnings Yield
-2.07
FreeCashFlow Yield
-0.19
Market Cap
0,05 Bil.
Enterprise Value
0,46 Bil.
Graham Number
24.53
Graham NetNet
-19.16

Income Statement Metrics

Net Income per Share
-3.82
Income Quality
-0.15
ROE
-0.43
Return On Assets
-0.13
Return On Capital Employed
-0.22
Net Income per EBT
0.87
EBT Per Ebit
1.83
Ebit per Revenue
-0.12
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
0.16
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.16
Operating Profit Margin
-0.12
Pretax Profit Margin
-0.23
Net Profit Margin
-0.2

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.55
Free CashFlow per Share
-0.34
Capex to Operating CashFlow
1.62
Capex to Revenue
0.05
Capex to Depreciation
0.36
Return on Invested Capital
-0.09
Return on Tangible Assets
-0.25
Days Sales Outstanding
49.31
Days Payables Outstanding
24.69
Days of Inventory on Hand
51.12
Receivables Turnover
7.4
Payables Turnover
14.78
Inventory Turnover
7.14
Capex per Share
0.89

Balance Sheet

Cash per Share
0,56
Book Value per Share
7,01
Tangible Book Value per Share
-7.49
Shareholders Equity per Share
7.01
Interest Debt per Share
16.92
Debt to Equity
2.16
Debt to Assets
0.51
Net Debt to EBITDA
145.53
Current Ratio
0.31
Tangible Asset Value
-0,19 Bil.
Net Current Asset Value
-0,44 Bil.
Invested Capital
275905000
Working Capital
-0,34 Bil.
Intangibles to Total Assets
0.49
Average Receivables
0,07 Bil.
Average Payables
0,03 Bil.
Average Inventory
62684999.5
Debt to Market Cap
8.23

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Inotiv, Inc. Dividends
Year Dividends Growth

Inotiv, Inc. Profile

About Inotiv, Inc.

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

CEO
Mr. Robert W. Leasure Jr.
Employee
1.955
Address
2701 Kent Avenue
West Lafayette, 47906-1382

Inotiv, Inc. Executives & BODs

Inotiv, Inc. Executives & BODs
# Name Age
1 Dr. Adrian Hardy Ph.D.
Chief Commercial Officer
70
2 Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D.
Chief Strategy Officer & Director
70
3 Mr. John Gregory Beattie DSA
Chief Operating Officer of DSA
70
4 Ms. Andrea Castetter
SVice President of General Counsel, Corporate Secretary & Chief Compliance Officer
70
5 Ms. Lizanne Muller
Group President of RMS
70
6 Mr. Jeffrey Arthur Krupp
Chief Human Resources Officer
70
7 Dr. Peter T. Kissinger
Founder, Chairman Emeritus & Scientific Advisor
70
8 Ms. Beth A. Taylor CPA
Senior Vice President of Finance & Chief Financial Officer
70
9 Mr. Robert W. Leasure Jr.
President, Chief Executive Officer & Director
70
10 Mr. Brennan Freeman
Vice President of Finance, Principal Accounting Officer & Corporate Controller
70

Inotiv, Inc. Competitors